Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 11, 2019
Daily News
December 11, 2019
- Astellas Charging Ahead with Immuno-Oncology Initiative to Save Non-Responders: Chief
December 11, 2019
- Adcetris Posts Positive Follow-Up Data for 1st-Line Use: Takeda/Seattle Genetics
December 11, 2019
- Maruho Grabs Japan Sales Rights to Peripheral Neuropathy Drug, Near 10% Stake in Solasia
December 11, 2019
- Cosentyx, Lumicef Get Orphan Status for Add’l Indications
December 11, 2019
- Chugai Expanding Target Range, MOAs in Antibody Drug Discovery with Its Engineering Technologies
December 11, 2019
- 1st Patient Dosed in Japan PII for Daiichi Sankyo’s ATL Drug
December 11, 2019
- Nobelpharma’s Retympa, Senju’s Aibeta Now Available
December 11, 2019
- “Third Price Revision” Eyed for Expansion of Comparator PMP Deduction Rule
December 11, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…